Advantages and application value of Lorlatinib/lorlatinib tablets (Lolatinib) in brain metastasis of non-small cell lung cancer

1. Clinical positioning and significance of lorlatinib

Non-small cell lung cancer (NSCLC) is one of the cancer types with the highest morbidity and mortality in the world. Although the proportion of patients with ALK-positive mutations is small, they are extremely dependent on precision treatment. Lorlatinib (trade name: LORBRENA/Borrena) is currently the third generation representative drug in the field of ALK inhibitors. With its unique molecular structure and breakthrough clinical efficacy, it has gradually become an important treatment option for patients with ALK-positive metastatic NSCLC. Since its first approval by the U.S. FDA in 2018, lorlatinib has been approved in many countries around the world, and will enter the Chinese market in 2022 and be included in medical insurance, bringing accessibility to more patients.

xa0

2. Indications and treatment population scope

According to the latest international guidelines, lorlatinib is suitable for adult patients with ALK-positive metastatic NSCLC. Especially after resistance to first- and second-generation ALK inhibitors (such as crizotinib, alectinib, and brigatinib), lorlatinib can effectively overcome multiple drug-resistant mutations. In addition, clinical data show that lorlatinib has significant advantages in the control of intracranial metastases and can better prolong patient survival and improve quality of life. This feature makes it irreplaceable in the treatment sequence of ALK-positive NSCLC.

xa0

3. Recommended usage and dosage and clinical practice experience

The recommended dose of lorlatinib is 100mg orally administered dailyThe patient needs to swallow the tablet whole, which can be taken with food or separately. Due to the special mechanism of action of the drug, patients are advised to strictly follow the doctor's instructions and are not allowed to increase or decrease the dosage or stop the drug without authorization. In clinical practice, doctors often adjust the dosage appropriately based on the patient's tolerance and adverse reactions, but generally maintain regular dosage once a day. Compared with early ALK inhibitors, lorlatinib has higher requirements for drug compliance, so patient education is particularly important.

xa0

4. Innovative breakthroughs in mechanism of action

Lorlatinib is a highly selectiveALK/ROS1 inhibitor that maintains activity against multiple drug-resistant mutation sites (such as G1202R, I1171T, etc.). Its molecular structure design emphasizes the ability to cross the blood-brain barrier, allowing the drug to exert significant anti-tumor effects in the central nervous system. In in vivo and in vitro studies, lorlatinib has demonstrated strong inhibition of brain metastases, which is its core advantage that distinguishes it from other ALK inhibitors.

xa0

5. Adverse reactions and management strategies

In actual use, the most common adverse reactions of lorlatinib include dyslipidemia (significant increase in levels), weight gain, nervous system-related side effects (cognitive changes, mood swings), edema, and peripheral neuropathy. Most adverse reactions can be controlled through auxiliary treatment with lipid-lowering drugs, dose adjustment, and lifestyle intervention. It is worth noting that some patients can still maintain a good quality of life after long-term medication. Therefore, doctors need to dynamically monitor blood lipid levels and cognitive function during treatment and adjust the plan in a timely manner.

xa0

6. Market structure of original drugs and generic drugs

The original drug was developed by Pfizer and has been launched in Europe, the United States and China. The Chinese trade name is "Borina". In China, the common specifications are 90 tablets of 25mg and 30 tablets of 100mg. After medical insurance reimbursement, the proportion of patients paying out of pocket has dropped significantly, and the market price is around 20,000 yuan. In comparison, prices in Hong Kong, European and American markets are generally higher, while prices of original drugs in Türkiye and other places are relatively low. In recent years, generic drugs with reliable quality have appeared in some countries and regions, that is, generic drugs that have passed consistency evaluation. The price is usually about one-tenth of the original drug. For example, the generic version produced in Laos is only sold for about 1,000 yuan, which provides patients with more choices.

xa0

xa0

7. Price comparison and medical insurance reimbursement details

The global price of lorlatinib varies greatly, and its accessibility has been significantly improved in China due to its inclusion in medical insurance. Taking 100mg*30 tablets as an example, the out-of-pocket price after medical insurance in China is about over 10,000 yuan, while the price before medical insurance negotiation may be close to 30,000 yuan. Pricing in European and American markets remains between US$4,000 and US$6,000, and patient insurance reimbursement ratios vary greatly. For patients who are not covered by medical insurance, some cross-border drug purchase channels provide generic drug versions at prices as low as RMB 1,000-2,000. Although there is a price gap, patients need to choose channels carefully to ensure the quality and legality of drugs.

xa0

8. The latest clinical research and cutting-edge trends

Recent overseas clinical studies have been continuously updated to explore the application potential of lorlatinib in first-line treatment. Some studies suggest that lorlatinib also exhibits potent anti-tumor activity and intracranial response rates in patients who have not used other ALK inhibitors. This provides a basis for future guideline updates and treatment path adjustments. In addition, as the mechanisms of resistance continue to be revealed, research on lorlatinib combined with immunotherapy, chemotherapy or other targeted drugs is also ongoing, and may further expand its application boundaries.

xa0

9. The practical significance of combining current affairs

Currently, the global competition for precision treatment of lung cancer is becoming increasingly fierce, and drug research and development and medical insurance policy reform complement each other. The dynamic adjustment of China's medical insurance catalog and the rapid introduction of innovative drugs have promoted the clinical application of new drugs such as lorlatinib. At the same time, with the advancement of the national centralized procurement policy, the speed of generic drugs entering the market will accelerate in the future, which is expected to further reduce drug costs. This is not only beneficial to patients, but also injects new impetus into the entire lung cancer treatment ecosystem.

xa0

xa0

10. Summary and Outlook

As an important milestone in the treatment of ALK-positive NSCLClorlatinib’s core advantages lie in its strong intracranial activity and ability to cover multiple drug-resistant mutations. With the release of more clinical research data around the world, lorlatinib's status in first-line treatment may further increase. In the future, the competition between original drugs and generic drugs, the continued optimization of medical insurance policies, and the popularization of precision medicine concepts will all affect the market structure and clinical value of lorlatinib. For patients, lorlatinib is not only a drug that prolongs survival, but also represents the hope of the "precision medicine" era.

xa0

Overseas reference materials:

https://en.wikipedia.org/wiki/Lorlatinib

FDA - Lorlatinib Approval History

https://go.drugbank.com/drugs/DB12130

https://www.lorbrena.com/